WHO ICTRP trial
SAFE: Sequre for Adenomyosis and Fibroid Embolisation
NL-OMON52676 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON52676 |
|---|---|
| Public title | SAFE: Sequre for Adenomyosis and Fibroid Embolisation |
| Scientific title | SAFE: Sequre for Adenomyosis and Fibroid Embolisation - SAFE |
| Primary sponsor | Sint Elisabeth Ziekenhuis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | uterus fibroids and adenomyosis;10038595;10013326;10003184;uterus fibroids and adenomyosis |
| Interventions | Embolization of myomas and/or adenomyosis (UAE) with the microcatheter 2.8F, performed by experienced intervention radiologists. Results are compared with retrospective status studies. ;adenomyosis;embolisation;fibroid;microcatheter |
| Registration date | Jun 16, 2022 |
| Target size | 30 |
| Secondary IDs | NL74393.028.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: